N-propan-2-yl-1,4,5,6-tetrahydropyrimidin-2-amine | 871128-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-propan-2-yl-1,4,5,6-tetrahydropyrimidin-2-amine
• CAS: 871128-09-5
• 化学式: C₇H₁₅N₃
• mdl: MFCD26131809
• 分子量: 141.216
• InChiKey: QNARELDSMZEEQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,3-丙二胺 、 N,N'-二异丙基碳二亚胺 在 [ς:η1:η5-(OCH2)(Me2NCH2)C2B9H9]Ti-(NMe2) 作用下， 以 甲苯 为溶剂， 反应 120.0h， 以65%的产率得到N-propan-2-yl-1,4,5,6-tetrahydropyrimidin-2-amine
  参考文献：
  名称：

  二酰胺/三胺和碳二亚胺催化钛酰胺催化合成环胍

  摘要：

  报道了钛碳碳烷单酰胺催化的由市售二胺/三胺和碳二亚胺一步合成单/双环胍。还提出了反应机理。

  DOI：

  10.1021/ol201752e

文献信息

• Efficient Synthesis of 2‐(<i>N</i>‐Substituted)‐2‐imidazolines and 2‐(<i>N</i>‐Substituted)‐1,4,5,6‐tetrahydropyrimidines
  作者：Wai Ming Kan、Shih‐Hsun Lin、Ching‐Yuh Chern

  DOI：10.1080/00397910500213005

  日期：2005.10.1

  Abstract A general method for the preparation of 2‐(N‐Substituted)‐2‐imidazolines and 2‐(N‐Substituted)‐1,4,5,6‐tetrahydropyrimidines is described. These heterocycles can be synthesized from their respective anilines with 2‐chloro‐2‐imidazoline or 2‐chloro‐1,4,5,6‐tetrahydropyrimidine, generated in situ from imidazolidin‐2‐one and tetrahydropyrimidin‐2(1H)‐one activated by dimethyl chlorophosphate

  摘要描述了制备 2-(N-取代)-2-咪唑啉和 2-(N-取代)-1,4,5,6-四氢嘧啶的一般方法。这些杂环可以由它们各自的苯胺与 2-氯-2-咪唑啉或 2-氯-1,4,5,6-四氢嘧啶合成，由咪唑啉-2-酮和四氢嘧啶-2(1H)-酮原位生成氯磷酸二甲酯活化，收率良好。
• RILUZOLE PRODRUGS AND THEIR USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180036290A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的制药组合物包括替代利鲁唑前药，通过释放利鲁唑治疗包括黑色素瘤、乳腺癌、脑癌和前列腺癌等癌症。利鲁唑的前药具有增强的肝代谢稳定性，并通过口服途径输送到全身循环中，然后通过酶促或一般的生物物理释放过程在血浆中裂解释放利鲁唑。
• ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE
  申请人：The Regents of the University of California

  公开号：US20160264566A1

  公开（公告）日：2016-09-15

  Provided herein, inter alia, are methods and compositions for inhibiting αvβ1 integrin and for treating fibrosis.

  本文提供了抑制αvβ1整合素和治疗纤维化的方法和组合物等内容。
• MALT1 inhibitors and uses thereof
  申请人：Cornell University

  公开号：US10711036B2

  公开（公告）日：2020-07-14

  Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).

  本文提供的式(I)化合物及其药物组合物可用作 MALT1 抑制剂。还提供了通过施用式（I）化合物治疗增殖性疾病（如癌症（如非霍奇金淋巴瘤、弥漫大 B 细胞淋巴瘤、MALT 淋巴瘤）、良性肿瘤、与血管生成相关的疾病、自身免疫性疾病、炎症性疾病、自身炎症性疾病）。
• Pyrrole amides as alpha V integrin inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10717736B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)化合物或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αv整合素的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含αv整合素失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。